Profusa, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $PFSA in the last 30 days.
See all $PFSA insider activity →Profusa amended two convertible notes with Ascent Partners Fund, setting a $0.338 floor price and VWAP-based conversion terms. The notes, maturing in April 2027, have principal amounts of $555,555.55 and $1,111,111.11. Share reserves are set at 150% of the floor price, and anti-dilution provisions were waived on other notes.
Profusa, Inc. (PFSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously disclosed, the Company is party to a Securities Purchase Agreement, dated as of February 11, 2025 (as amended, the “Purchase Agreement”), by and among the Company, Ascent Partners Fund LLC, a Delaware limited lia
Biotech stocks APUS, PFSA, GCTK, and ARCT saw notable moves. APUS surged 130% without specific news, plans Phase 3 trial for Apitox. PFSA up 49.14% after ISO 13485 certification progress. GCTK raised $3.1M via stock offering, up 25.62%. ARCT rose 6.77% on Phase 2 results and LUNAR 2.0 platform news. Q2 losses reported for APUS.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning PFSA (Profusa, Inc.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent PFSA coverage spans corporate actions, market movers and regulation.
The amendment tightens conversion mechanics, potentially diluting existing shareholders if conversion occurs at lower prices.
Amendments tighten conversion terms, limiting dilution and improving noteholder protection.
Regulatory progress may unlock European market sales.
The certification may enable EU market entry, supporting future revenue growth.
The vote authorizes the board to execute a 1‑for‑2 to 1‑for‑12 reverse split within two years, which could boost share price if approved.
AlphAI scores every news story that mentions PFSA with an AI model for sentiment and relevance, and aggregates insider trades from Profusa, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Profusa amended two convertible notes with Ascent Partners Fund, setting a $0.338 floor price and VWAP-based conversion terms. The notes, maturing in April 2027, have principal amounts of $555,555.55 and $1,111,111.11. Share reserves are set at 150% of the floor price, and anti-dilution provisions were waived on other notes.
1 min readProfusa, Inc. (PFSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously disclosed, the Company is party to a Securities Purchase Agreement, dated as of February 11, 2025 (as amended, the “Purchase Agreement”), by and among the Company, Ascent Partners Fund LLC, a Delaware limited lia
2 min readBiotech stocks APUS, PFSA, GCTK, and ARCT saw notable moves. APUS surged 130% without specific news, plans Phase 3 trial for Apitox. PFSA up 49.14% after ISO 13485 certification progress. GCTK raised $3.1M via stock offering, up 25.62%. ARCT rose 6.77% on Phase 2 results and LUNAR 2.0 platform news. Q2 losses reported for APUS.
3 min readProfusa (PFSA) received a positive ISO 13485 decision from GMED, advancing its Lumee Oxygen Platform toward CE marking in the EU. The platform monitors tissue oxygen levels. Profusa expects ISO certification in early October but cautions on timing uncertainties. PFSA stock is up 86.82% in pre-market trading.
1 min readProfusa, Inc. (PFSA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On September 18, 2026, the Company held a Special Meeting of Stockholders (the “Meeting”), which was convened virtually at www.virtualshareholdermeeting.com/PFSA2026SM , pursuant to notice duly given. Definitive proxy
1 min readProfusa, Inc. (PFSA) raised $350,000 via a senior secured convertible note from Ascent Partners Fund. The note has a 7% interest rate, matures by September 16, 2027, and is convertible at $4.28 per share. Proceeds aim to bolster liquidity, with note repayment conditions tied to future fundraisings.
1 min readProfusa, Inc. (PFSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Senior Secured Convertible Promissory Note On September 16, 2026, Profusa, Inc., a Delaware corporation (the “Company”), completed an additional closing under that certain Securities Purchase Agreement, dated as of February 11
1 min readProfusa, Inc. (PFSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Senior Secured Convertible Promissory Note On September 1, 2026, Profusa, Inc., a Delaware corporation (the “Company”), completed an additional closing under that certain Securities Purchase Agreement, dated as of February 11,
1 min readProfusa (PFSA) reported progress on conditions for its potential G3 Vision Labs acquisition, but Q2 2026 results showed a widened net loss of $8.8M and limited cash. The company is restructuring its balance sheet with debt-to-equity exchanges. G3's audits are expected by mid-September. PFSA ended June with $719K in cash and $28.2M in liabilities.
3 min readProfusa raised $714,285.72 via a senior secured convertible note at 7% interest, maturing in 2027, with a $1.07 conversion price. It also agreed to exchange $6.14M in debt for Series A Preferred Stock, implying a $4.28 conversion price, to simplify its capital structure.
1 min read
